{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:31:51Z","timestamp":1762867911349,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.endien.2023.05.012","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T06:56:04Z","timestamp":1685602564000},"page":"501-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus document for lipid profile testing and reporting in Spanish clinical laboratories"],"prefix":"10.1016","volume":"70","author":[{"given":"Teresa","family":"Arrobas Velilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Campuzano Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rodr\u00edguez Pi\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco","family":"Valderrama Marcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio M.","family":"Botana L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morais L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Garc\u00eda Donaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Obaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Castilla Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Pallares Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Egocheaga Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Salgueira Lazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Mar","family":"Castellanos Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez Doblas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bu\u00f1o Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.endien.2023.05.012_bib0005","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.endien.2023.05.012_bib0010","unstructured":"INE Defunciones por causas (lista reducida) por sexo y grupos de edad (7947). INE. [accedido 16 febrero 2022]. Available at: https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=7947#!tabs-tabla."},{"key":"10.1016\/j.endien.2023.05.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0020","first-page":"30.e1","article-title":"Dislipidemias: un reto pendiente en prevenci\u00f3n cardiovascular. Documento de consenso CEIPC\/SEA","volume":"137","author":"Royo Bordonada","year":"2011","journal-title":"Med Cl\u00ednica."},{"key":"10.1016\/j.endien.2023.05.012_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis."},{"issue":"zwaa047","key":"10.1016\/j.endien.2023.05.012_bib0030","article-title":"EU-wide cross- sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol."},{"issue":"4","key":"10.1016\/j.endien.2023.05.012_bib0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","article-title":"Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study","volume":"64","author":"Gonz\u00e1lez-Juanatey","year":"2011","journal-title":"Rev Esp Cardiol Engl Ed."},{"issue":"22","key":"10.1016\/j.endien.2023.05.012_bib0040","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining When to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"ehab484","key":"10.1016\/j.endien.2023.05.012_bib0045","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.endien.2023.05.012_bib0050","article-title":"Gu\u00eda ESC 2021 sobre la prevenci\u00f3n de la enfermedad cardiovascular en la pr\u00e1ctica cl\u00ednica: Con la contribuci\u00f3n especial de la European Association of Preventive Cardiology (EAPC)","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nrl.2020.07.027","article-title":"Dislipidemias y prevenci\u00f3n del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espa\u00f1ola de Neurolog\u00eda","volume":"37","author":"Palacio-Portilla","year":"2022","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.endien.2023.05.012_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.arteri.2021.11.003","article-title":"Est\u00e1ndares SEA 2022 para el control global del riesgo cardiovascular","author":"Mostaza","year":"2022","journal-title":"Cl\u00ednica E Investig En Arterioscler"},{"issue":"2","key":"10.1016\/j.endien.2023.05.012_bib0065","first-page":"85","article-title":"Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines","volume":"33","author":"Armario","year":"2021","journal-title":"Clin Investig Arterioscler"},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0070","first-page":"36","article-title":"Homogeneizaci\u00f3n de los valores del perfil lip\u00eddico","volume":"30","author":"Pedro-Botet","year":"2018","journal-title":"Clin Investig Arterioscler"},{"issue":"07","key":"10.1016\/j.endien.2023.05.012_bib0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.recesp.2018.01.004","article-title":"El informe anal\u00edtico ideal del perfil lip\u00eddico. Necesidad de un consenso","volume":"71","author":"Pedro-Botet","year":"2018","journal-title":"Rev Esp Cardiol."},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.1976.03270030015018","article-title":"Correct levels of serum cholesterol: average vs normal vs optimal","volume":"236","author":"Wright","year":"1976","journal-title":"JAMA."},{"key":"10.1016\/j.endien.2023.05.012_bib0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis."},{"issue":"5","key":"10.1016\/j.endien.2023.05.012_bib0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group","volume":"15","author":"Wilson","year":"2021","journal-title":"J Clin Lipidol."},{"issue":"12","key":"10.1016\/j.endien.2023.05.012_bib0095","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.1992.03480120090039","article-title":"Blood lipid measurements: variations and practical utility","volume":"267","author":"Cooper","year":"1992","journal-title":"JAMA."},{"issue":"Supplement 1","key":"10.1016\/j.endien.2023.05.012_bib0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National lipid association annual summary of clinical lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.endien.2023.05.012_bib0105","series-title":"Endotext","article-title":"Medication induced changes in lipid and lipoproteins","author":"Herink","year":"2000"},{"issue":"7","key":"10.1016\/j.endien.2023.05.012_bib0110","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res."},{"key":"10.1016\/j.endien.2023.05.012_bib0115","series-title":"Endotext","article-title":"The effect of inflammation and infection on lipids and lipoproteins","author":"Feingold","year":"2000"},{"issue":"5","key":"10.1016\/j.endien.2023.05.012_bib0120","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/01.CCM.0000059724.08290.51","article-title":"Lipoprotein metabolism in patients with severe sepsis","volume":"31","author":"van Leeuwen","year":"2003","journal-title":"Crit Care Med."},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12944-021-01603-9","article-title":"Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis","volume":"20","author":"P\u00e1ez-Guill\u00e1n","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.endien.2023.05.012_bib0130","first-page":"517","article-title":"Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction","volume":"14","author":"Shrivastava","year":"2015","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/j.endien.2023.05.012_bib0135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1378\/chest.120.4.1196","article-title":"Effect of acute myocardial infarction on cholesterol ratios","volume":"120","author":"Wattanasuwan","year":"2001","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"10.1016\/j.endien.2023.05.012_bib0145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by thnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res."},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis."},{"issue":"25","key":"10.1016\/j.endien.2023.05.012_bib0155","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J."},{"issue":"10","key":"10.1016\/j.endien.2023.05.012_bib0160","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.endien.2023.05.012_bib0165","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a Novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA."},{"issue":"8","key":"10.1016\/j.endien.2023.05.012_bib0170","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"1","key":"10.1016\/j.endien.2023.05.012_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2023.05.012_bib0185","doi-asserted-by":"crossref","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation.","DOI":"10.1016\/j.jacc.2019.03.010"},{"issue":"25","key":"10.1016\/j.endien.2023.05.012_bib0190","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"issue":"21","key":"10.1016\/j.endien.2023.05.012_bib0195","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"S0828-282X","author":"Pearson","year":"2021","journal-title":"Can J Cardiol."},{"issue":"4","key":"10.1016\/j.endien.2023.05.012_bib0200","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med."},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of Apolipoprotein B\u2013containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.endien.2023.05.012_bib0210","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J."},{"issue":"25","key":"10.1016\/j.endien.2023.05.012_bib0215","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J."},{"issue":"18","key":"10.1016\/j.endien.2023.05.012_bib0220","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.endien.2023.05.012_bib0230","first-page":"219","article-title":"Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale\u00ae)","volume":"32","author":"Pint\u00f3","year":"2020","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.endien.2023.05.012_bib0235","unstructured":"WHO Human Genetics Programme Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. World Health Organization; 1999."},{"issue":"4","key":"10.1016\/j.endien.2023.05.012_bib0240","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacl.2020.06.004","article-title":"A simplified diagnosis algorithm for dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol."},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0245","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.endien.2023.05.012_bib0250","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","author":"Reyes-Soffer","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.endien.2023.05.012_bib0255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.endien.2023.05.012_bib0260","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.endien.2023.05.012_bib0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)- lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.endien.2023.05.012_bib0270","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.endien.2023.05.012_bib0275","first-page":"128","article-title":"Indicaciones de los inhibidores de proprote\u00edna convertasa subtilisina kexina 9 (PCSK9) en la pr\u00e1ctica cl\u00ednica. Recomendaciones de la Spanish Society of Arteriosclerosis (SEA) 2019","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscler"},{"issue":"10354","key":"10.1016\/j.endien.2023.05.012_bib0280","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.endien.2023.05.012_bib0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u00abFCS score\u00bb","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018023000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018023000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:18:33Z","timestamp":1762867113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018023000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2530018023000938"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2023.05.012","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document for lipid profile testing and reporting in Spanish clinical laboratories","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2023.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2023.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}